RxDoctor Payments Data

James Hill

Family · Florence, SCNPI 1881059244

Payments from drug & device makers

$9,134in general payments, 2019–2025

Across 384 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Medtronic$921
  • Boston Scientific$854
  • Novartis$845
  • AstraZeneca$792
  • Johnson & Johnson$608
  • plus $3K from 23 others

What the payments were for

  • Travel & lodging$1,67718%
  • Food & beverage$7,41381%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,134 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$154,910
Medicare patients
960
Services billed
3,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$102,959
EntrestoSacubitril/Valsartan83$69,158
MultaqDronedarone Hcl36$41,620
XareltoRivaroxaban28$30,496
Repatha SureclickEvolocumab15$18,055
JardianceEmpagliflozin22$14,262
Dofetilide12$2,979
Metoprolol Succinate242$2,307
Bumetanide31$1,142
Rosuvastatin Calcium67$1,108
Losartan Potassium99$1,080
Flecainide Acetate22$1,005
Nifedipine ErNifedipine27$782
Amlodipine Besylate101$707
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$352$102,959122 claims
NovartisEntresto$845$69,15883 claims
Sanofi-aventis U.S. LLCMultaq$55$41,62036 claims
Johnson & JohnsonXarelto$608$30,49628 claims
Boehringer IngelheimJardiance$235$14,26222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →